[Pitfalls and dilemmas in the decision-making process of diagnosis and treatment on gastrointestinal stromal tumor].

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor in the gastrointestinal tract. The successful application of molecular targeted agents has promoted the clinical diagnosis and treatment of GIST into the era of precision medicine. There are some pitfalls in the diagnosis (including preoperative diagnosis and pathological diagnosis), surgical treatment (including surgical procedure, minimally invasive surgery, and surgery for recurrent/metastatic GIST) and drug treatment (including duration of adjuvant therapy for very high risk GIST and timing of intervention during preoperative treatment) of GIST. In addition to difficulties of doctors, these pitfalls can also lead to waste of medical resources, and even endanger the health and life of patients. Each doctor engaged in the diagnosis and treatment of GIST needs to fully understand the biological characteristics and disease development pattern of GIST, and accurately recognize every possible trap in the clinical management. This paper analyzes the pitfalls and misunderstandings in various aspects of GIST diagnosis and treatment in order to provide clues for promoting more reasonable clinical decision-making.